Forest Laboratories, Inc.
909 Third Avenue
New York
New York
10022-4731
United States
Tel: 212-421-7850
Fax: 212-750-9152
Website: http://www.frx.com/
About Forest Laboratories, Inc.
Explore your potential. Discover the rewards.
At Forest Laboratories, we believe in the power of potential. As one of the fastest growing pharmaceutical companies, we are committed to developing a talented, diverse workforce where individuals can learn, achieve and grow.
Highly skilled scientific teams within our Forest Research Institute enable us to license compounds at virtually any stage—from preclinical development to products that are ready for FDA review—and then complete the development and regulatory work to successfully bring these new products to market. Our products, including Lexapro®, Namenda® and Benicar®, help treat a range of conditions such as depression, anxiety, Alzheimer’s disease and hypertension.
In addition to further developing our established therapeutic franchises (central nervous system, cardiovascular and respiratory), we are expanding the scope of our pipeline to address a wider range of health concerns that affect people every day, such as inflammation and pain. This growth is creating significant new career opportunities, and we invite energetic, skilled professionals to join Forest and contribute to our future success.
Employees are the engine of our rapid growth, and in return we offer the incentives and benefits for a healthy work/life balance.
For career opportunities on Long Island, New Jersey and NYC please visit: www.frx.com
Last Updated: 06-01-2006
404 articles about Forest Laboratories, Inc.
-
Forest Laboratories, Inc. Announces New FETZIMA™ (Levomilnacipran ER Capsules) Now Available In Pharmacies Throughout U.S.
12/19/2013
-
Forest Laboratories, Inc. Announces New FETZIMA™ (levomilnacipran ER capsules) Now Available In Pharmacies Throughout U.S.
12/19/2013
-
Forest Laboratories, Inc. Upsizes And Prices Offering Of $1.2 Billion Of Senior Notes Due 2021
12/6/2013
-
AstraZeneca PLC Said To Be Eyeing Forest Laboratories, Inc. Takeover Bid
12/4/2013
-
Forest Laboratories, Inc. To Trim Jobs In $500 Million Restructuring
12/2/2013
-
Forest Laboratories, Inc. Snags Rights To Saphris® (asenapine) From Merck & Co., Inc. For $240 Million
12/2/2013
-
FDA Declines To Approve Forest Laboratories, Inc., Gedeon Richter Ltd.'s New Antipsychotic Drug
11/22/2013
-
Forest Laboratories, Inc. Announces Settlement of BYSTOLIC® Patent Litigation
11/7/2013
-
Forest Laboratories, Inc. Names Alex Kelly Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations
10/25/2013
-
New CEO Signals Strategic Changes at Forest Laboratories, Inc.
10/23/2013
-
Forest Laboratories, Inc. Reports Fiscal Year Second Quarter 2014 Diluted Earnings Per Share of $0.26 Including Effect of $0.10 Per Share of Acquisition Amortization
10/22/2013
-
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Second Quarter Earnings
10/2/2013
-
Forest Laboratories, Inc. Files Lawsuits Aagainst Several Companies for Infringement of Savella® Patents
9/24/2013
-
Forest Laboratories, Inc.'s Ceftazidime/avibactam Combination Receives Qualified Infectious Disease Product (QIDP) Designation From FDA
9/13/2013
-
Forest Laboratories, Inc. Names Brent Saunders CEO and President
9/10/2013
-
Forest Laboratories, Inc., Almirall Delay FDA Filing of Combo COPD Drug
8/15/2013
-
Amerigen Pharmaceuticals Today Announced It Had Entered Into a Collaboration Agreement With Forest Laboratories, Inc. Regarding the Development of a Number of Specialty Generic Products.
7/31/2013
-
Forest Laboratories, Inc. and Pierre Fabre Grab FDA OK on Depression Drug
7/30/2013
-
Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2014 Diluted Earnings Per Share of $0.09 Including Effect of $0.09 Per Share of Acquisition Amortization
7/23/2013
-
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation
7/22/2013